Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE trial
Conclusions: In patients with AF, apixaban more often prevented stroke or systemic embolism and death and caused less bleeding than warfarin, regardless of the presence of prior CAD. Given the common occurrence of AF and CAD and the higher rates of cardiovascular events and death, our results indicate that apixaban may be a better treatment option than warfarin for these high-risk patients.
Source: International Journal of Cardiology - Category: Cardiology Authors: Maria Cecilia Bahit, Renato D. Lopes, Daniel M. Wojdyla, Stefan H. Hohnloser, John H. Alexander, Basil S. Lewis, Philip E. Aylward, Freek W.A. Verheugt, Matyas Keltai, Rafael Diaz, Michael Hanna, Christopher B. Granger, Lars Wallentin Tags: Original Articles Source Type: research
More News: Aspirin | Atrial Fibrillation | Bleeding | Cardiology | Cardiovascular | Coumadin | Diabetes | Endocrinology | Heart | Heart Attack | Hemorrhagic Stroke | Hypertension | Stroke | Warfarin